Kaisa Huotari

Kaisa Huotari

Auto-generated profile, based on publicly available information

Kaisa Huotari

Department of Infectious diseases, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2015 in Acta Orthopaedica
Verified
Journal Article
Open access
KHKaisa Huotari
Kaisa Huotari
MPMikko Peltola
Mikko Peltola
EJEsa Jämsen
Esa Jämsen
Late prosthetic joint infections (PJIs) are a growing medical challenge as more and more joint replacements are being performed and the expected lifespan of patients is increasing. We analyzed the incidence rate of late PJI and its temporal trends in a nationwide population. 112,708 primary hip and knee replacements performed due to primary osteoarthritis (OA) between 1998 and 2009 were followed for a median time of 5 (1-13) years, using data from nationwide Finnish health registries. Late PJI was detected > 2 years postoperatively, and very late PJI was detected > 5 years postoperatively. During the follow-up, involving 619,299 prosthesis-years, 1,345 PJIs were registered: cumulative incidence 1.20% (95% CI: 1.13-1.26) (for knees, 1.41%; for hips, 0.92%). The incidence rate of late PJI was 0.069% per prosthesis-year (CI: 0.061-0.078), and it was greater after knee replacement than after hip replacement (0.080% vs. 0.057%, p = 0.006). The incidence rate of very late PJI was 0.051% per prosthesis-year (CI: 0.042-0.063), 0.058% for knees and 0.044% for hips (p = 0.2). The incidence rate of late PJI varied between 0.041% and 0.107% during the years of observation without any temporal trend (incidence rate ratio (IRR) = 0.98, 95% CI: 0.93-1.03). Very late PJI increased from 0.026% in 2004 to 0.056% in 2010 (IRR = 1.11, 95% CI: 1.02-1.20). In our nationwide study, the incidence rate of late PJI after hip or knee arthroplasty was approximately 0.07% per prosthesis-year. The incidence of very late PJI appeared to increase.

1 February 2013 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
MOMikko T Ovaska
Mikko T Ovaska
TMTatu J Mäkinen
Tatu J Mäkinen
RMRami Madanat
Rami Madanat
KHKaisa Huotari
Kaisa Huotari
TVTero Vahlberg
Tero Vahlberg
JLJan Lindahl
Jan Lindahl
Es of treatment of Legg-Calvé-Perthes disease, we evaluated a method of quantifying the shape and size of the femoral head and the femoral-acetabular relationship from computer images of anteroposterior and lateral radiographs with the help of image-analysis software. Methods: Radiographs of 121 skeletally mature individuals with healed Legg-Calvé-Perthes disease were analyzed, and the sphericity deviation score, femoral head enlargement, femoral neck growth inhibition, and composite femoral congruency arc were calculated. Results: Each of these measurements was reproducible, with distinctly different values for hips in each of the Stulberg classes. Measures of sphericity and congruence (the sphericity deviation score and the composite femoral congruency arc) could very clearly discriminate between spherical and aspherical hips, and there was a strong correlation between these two measurements. Conclusions: The study shows that it is possible to have reliable quantitative measures of the outcome of Legg-Calvé-Perthes disease at skeletal maturity....

1 January 2019 in Journal of Infection
Verified
Journal Article
Closed access
MWMarjan Wouthuyzen-Bakker
Marjan Wouthuyzen-Bakker
MSMarine Sebillotte
Marine Sebillotte
JLJose Lomas
Jose Lomas
ATAdrian Taylor
Adrian Taylor
EBEva Benavent
Eva Benavent
ASAlex Soriano
Alex Soriano

23 March 2017 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
Jaime Lora-TamayoJaime Lora-Tamayo
Jaime Lora-Tamayo
ÉSÉric Senneville
Éric Senneville
ARAlba Ribera
Alba Ribera
LBLouis Bernard
Louis Bernard
MDMichel Dupon
Michel Dupon
JAJavier Ariza
Javier Ariza
Streptococci are not an infrequent cause of periprosthetic joint infection (PJI). Management by debridement, antibiotics, and implant retention (DAIR) is thought to produce a good prognosis, but little is known about the real likelihood of success. A retrospective, observational, multicenter, international study was performed during 2003–2012. Eligible patients had a streptococcal PJI that was managed with DAIR. The primary endpoint was failure, defined as death related to infection, relapse/persistence of infection, or the need for salvage therapy. Overall, 462 cases were included (median age 72 years, 50% men). The most frequent species was Streptococcus agalactiae (34%), and 52% of all cases were hematogenous. Antibiotic treatment was primarily using β-lactams, and 37% of patients received rifampin. Outcomes were evaluable in 444 patients: failure occurred in 187 (42.1%; 95% confidence interval, 37.5%–46.7%) after a median of 62 days from debridement; patients without failure were followed up for a median of 802 days. Independent predictors (hazard ratios) of failure were rheumatoid arthritis (2.36), late post-surgical infection (2.20), and bacteremia (1.69). Independent predictors of success were exchange of removable components (0.60), early use of rifampin (0.98 per day of treatment within the first 30 days), and long treatments (≥21 days) with β-lactams, either as monotherapy (0.48) or in combination with rifampin (0.34). This is the largest series to our knowledge of streptococcal PJI managed by DAIR, showing a worse prognosis than previously reported. The beneficial effects of exchanging the removable components and of β-lactams are confirmed and maybe also a potential benefit from adding rifampin.

11 September 2006 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
EREeva Ruotsalainen
Eeva Ruotsalainen
KSKari Sammalkorpi
Kari Sammalkorpi
JLJanne Laine
Janne Laine
KHKaisa Huotari
Kaisa Huotari
SSSeppo Sarna
Seppo Sarna
AJAsko Järvinen
Asko Järvinen
Endocarditis is a common complication in Staphylococcus aureus bacteremia (SAB). We compared risk factors, clinical manifestations, and outcome in a large, prospective cohort of patients with S. aureus endocarditis in injection drug users (IDUs) and in nonaddicts. Four hundred and thirty consecutive adult patients with SAB were prospectively followed up for 3 months. Definite or possible endocarditis by modified Duke criteria was found in 74 patients: 20 patients were IDUs and 54 nonaddicts. Endocarditis was more common in SAB among drug abusers (46%) than in nonaddicts (14%) (odds ratio [OR], 5.12; 95% confidence interval [CI], 2.65–9.91; P < 0.001). IDUs were significantly younger (27 ± 15 vs 65 ± 15 years, P < 0.001), had less ultimately or rapidly fatal underlying diseases (0% vs 37%, P < 0.001) or predisposing heart diseases (20% vs 50%, P = 0.03), and their SAB was more often community-acquired (95% vs 39%, P < 0.001). Right-sided endocarditis was observed in 60% of IDUs whereas 93% of nonaddicts had left-sided involvement (P < 0.001). An extracardiac deep infection was found in 85% of IDUs and in 89% of nonaddicts (P = 0.70). Arterial thromboembolic events and severe sepsis were also equally common in both groups. There was no difference in mortality between the groups at 7 days, but at 3 months it was lower among IDUs (10%) compared with nonaddicts (39%) (OR, 5.73; 95% CI, 1.20–27.25; P = 0.02). S. aureus endocarditis in IDUs was associated with as high complication rates including extracardiac deep infections, thromboembolic events, or severe sepsis as in nonaddicts. Injection drug abuse in accordance with younger age and lack of underlying diseases were associated with lower mortality, but after adjusting by age and underlying diseases injection drug abuse was not significantly associated with mortality.

1 September 2019 in Journal of Infection
Verified
Journal Article
Closed access
MWMarjan Wouthuyzen-Bakker
Marjan Wouthuyzen-Bakker
MSMarine Sebillotte
Marine Sebillotte
JLJose Lomas
Jose Lomas
BKBenjamin Kendrick
Benjamin Kendrick
EPEva Benavent Palomares
Eva Benavent Palomares
ASAlex Soriano
Alex Soriano